Recent Share Performance and Business Context

Ionis Pharmaceuticals (IONS) has drawn attention after recent trading, with the stock last closing at $75.13. The move comes against a backdrop of mixed short term returns and a longer track record of positive total returns.

Short term trading has been choppy, with a 1 day share price gain of 1.77% set against weaker recent share price returns year to date, while the 1 year total shareholder return of 113.20% points to strong longer term momentum.

If you are comparing Ionis with other health focused growth stories, this is a good moment to widen your watchlist with 40 healthcare AI stocks

With Ionis shares up strongly over the past year, trading below some valuation estimates yet still loss making, the key question is simple: are you looking at an undervalued growth story, or has the market already priced in what comes next?

Most Popular Narrative: 25.6% Undervalued

Ionis Pharmaceuticals' most followed valuation narrative pegs fair value at $100.92, well above the last close at $75.13, putting analyst expectations firmly in focus.

The rapid revenue growth and positive launch trajectory for Tryngolza in familial chylomicronemia syndrome (FCS), along with the imminent launch of Donidalorsen for HAE and multiple late-stage pipeline assets reading out or launching by 2027, are set to drive sustained, stepwise increases in top-line revenue and operating leverage as Ionis transitions from R&D-heavy to commercial-stage.

Curious what sits behind a fair value well above today's share price? This narrative leans on rapid revenue expansion, a sharp profit margin swing, and a rich future earnings multiple. Want to see which exact growth and profitability assumptions have to hold together to reach that $100.92 figure?

Result: Fair Value of $100.92 (UNDERVALUED)

However, this hinges on key approvals and data going to plan, and setbacks on late stage trials or pricing pressure in broader indications could quickly challenge that positive scenario.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another Angle On Valuation

So far the focus has been on analyst fair value at $100.92, but the SWS DCF model takes a different route and is even more aggressive, with a future cash flow value of $271.05. Both methods point to undervaluation, but the gap between $100.92 and $271.05 is large, so which yardstick do you trust more?

Next Steps

With sentiment skewed toward opportunity so far, this is the moment to look through the numbers yourself and pressure test every assumption. To see what investors are optimistic about, review the 2 key rewards.

Looking For More Investment Ideas?

If you stop with a single stock, you risk missing other opportunities that fit your style. Let the screener surface ideas while you stay in control.

• Target income first by scanning companies built around reliable payouts with the 10 dividend fortresses.
• Hunt for quality at a compelling price by reviewing companies flagged as potential bargains in the 47 high quality undervalued stocks.
• Prioritize resilience by shortlisting companies with sturdy finances using the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.